<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02831296</url>
  </required_header>
  <id_info>
    <org_study_id>2015P001934</org_study_id>
    <secondary_id>R01HD069045</secondary_id>
    <nct_id>NCT02831296</nct_id>
  </id_info>
  <brief_title>Prospective Evaluation of Infants With Spinal Muscular Atrophy:</brief_title>
  <acronym>SPOTSMA</acronym>
  <official_title>Prospective Evaluation of Infants With Spinal Muscular Atrophy: SPOT SMA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Massachusetts, Worcester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ARUP Laboratories</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Newborn Screening Translational Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>American College of Medical Genetics and Genomics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      SPOT SMA is a prospective NIH-supported clinical study targeting pre-symptomatic or recently
      diagnosed infants and children with Spinal Muscular Atrophy (SMA) types 1, 2, or 3 and their
      healthy control siblings less than 36 months of age at the time of study enrollment. The main
      objective of the study is to prospectively collect longitudinal clinical outcomes and provide
      counseling and education to parents of newly diagnosed children. The study will assess the
      impact of current standard of care management paradigms and interventions on health outcomes
      in newly diagnosed SMA infants and children with type 1, 2 or 3 and age appropriate controls.
      There is no investigational drug and no specific intervention in this study. Rather, the
      investigators will document outcomes related to current therapies provided to participating
      subjects, and will educate participants about possible clinical trial opportunities.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Overview of data to be collected from enrolled infants followed longitudinally and entered
      into the NBSTRN Longitudinal Pediatric Data Resource

        1. Past medical history relevant to pregnancy, delivery, complications in the immediate
           neonatal period, birth parameters, family history and any medical problems other than
           SMA (ie prematurity, etc)

        2. Ongoing medical history indicating problems related to the following areas:

           feeding, growth, respiratory status including use of cough assist and bilevel
           respiratory support, gastrointestinal issues, cardiac symptoms, neurologic symptoms or
           signs including muscle weakness, hospitalizations, ER visits, other adverse events

        3. Assessment of dietary intake and use of nutritional supplements

        4. Surgical history and ongoing documentation of assessments and need for g-tube, Nissen,
           tympanostomy, adenoidectomy/tonsillectomy or other airway surgeries, and orthopedic
           procedures

        5. Caregiver obtained developmental history and documentation of newly acquired and/or loss
           of previously acquired gross motor skills at the time of each visit

        6. Documentation of caregiver reported outcomes

        7. Documentation of anthropometric measures, vital signs, general physical examination
           parameters

        8. Neurological examination using standardized tools

        9. Time to death, permanent invasive ventilation and/or need for &gt; 16 hours/day of bilevel
           respiratory support

       10. Specific assessment of motor function as measured using age appropriate motor outcome
           measures such as: the Children's Hospital of Philadelphia Infant Tests of Neuromuscular
           Disorders (CHOP-INTEND), Test of Infant Motor Performance Screening Inventory, WHO motor
           milestones or others, and Hammersmith Functional Motor Scale for SMA Expanded for
           children 18 months and older

       11. Electrophysiologic studies such as maximum ulnar compound muscle action potential (CMAP)
           amplitude and area

       12. Documentation of range of motion, development of limb contractures and/or presence of
           scoliosis, lordosis, hip dysplasia or other orthopedic outcomes

       13. Additional optional exploratory biomarker assessments

       14. DEXA measurements to assess body composition and bone density

       15. The option to enroll in an autopsy study at the time of death to contribute samples to a
           research biorepository

      Normal control subjects such as unaffected siblings will undergo these same measurements, as
      applicable. Unaffected parents' participation will be limited to collection and banking of
      blood and cell lines.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Time to death and/or full time invasive ventilation or need for &gt; 16 hours/day of bilevel respiratory support</measure>
    <time_frame>At each visit (every 1-6 months depending on age)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Ulnar CMAP Amplitude</measure>
    <time_frame>At each visit (every 1-6 months depending on age)</time_frame>
    <description>Maximum ulnar compound muscle action potential (CMAP) amplitude and area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CHOP-INTEND</measure>
    <time_frame>At each visit (every 1-6 months depending on age, or until deemed no longer appropriate by PI/physical therapist)</time_frame>
    <description>Assessment of motor function in infants and children functioning at an infant level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WHO Motor Milestones</measure>
    <time_frame>At each visit (every 1-6 months depending on age)</time_frame>
    <description>Acquisition of gross motor milestones, per WHO guidelines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hammersmith Functional Motor Scale - Expanded</measure>
    <time_frame>At each visit (every 1-6 months depending on age, beginning when deemed appropriate by PI/physical therapist)</time_frame>
    <description>Assessment of motor function in subjects whose motor function exceeds that of an infant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hammersmith Infant Neurological Exam (HINE)</measure>
    <time_frame>At each visit (every 1-6 months depending on age, beginning when deemed appropriate by PI/physical therapist)</time_frame>
    <description>Assessment of neuromotor function in infants, general neurologic exam in infants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>Every 6 months</time_frame>
    <description>DEXA scans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone density</measure>
    <time_frame>Every 6 months</time_frame>
    <description>DEXA scans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for tube feeding</measure>
    <time_frame>At each visit (every 1-6 months depending on age)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caregiver Questionnaire total score and subscores</measure>
    <time_frame>At each visit (every 1-3 months depending on age and SMA type)</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Spinal Muscular Atrophy</condition>
  <arm_group>
    <arm_group_label>Affected Subjects &lt;36 Mos. of Age</arm_group_label>
    <description>Infants and children 36 months of age and younger at time of enrollment who have been genetically diagnosed with Spinal Muscular Atrophy (SMA)
The affected cohort will receive coordinated, multidisciplinary care including dietary intervention, respiratory monitoring, physical therapy, and genetic counseling. They will also undergo assessment of motor function, muscle action potential measurement, and body composition, as well as blood sample collection for DNA and biomarkers, and optional research skin biopsy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Unaffected Subjects &lt;36 Mos. of Age</arm_group_label>
    <description>Infants and children 36 months of age and younger who are not affected with SMA
The unaffected group will undergo the same assessments as the affected group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Unaffected Family Members</arm_group_label>
    <description>Parents and siblings of any age, without genetic diagnosis of SMA, who have family members enrolled in either of the Affected Infants/Children/Adults cohorts.
The unaffected siblings will undergo the same assessments as the affected group, where age-appropriate. Unaffected parents' participation will be limited to blood sample collection and optional research skin biopsy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Affected Subjects &gt;36 Mos. of Age</arm_group_label>
    <description>Children and adults &gt;36 months at time of enrollment who have been genetically diagnosed with Spinal Muscular Atrophy.
The older affected cohort will receive coordinated, multidisciplinary care including dietary intervention, respiratory monitoring, physical therapy, and genetic counseling. They will also undergo assessment of motor function, muscle action potential measurement, and body composition, as well as blood sample collection for DNA and biomarkers, and optional research skin biopsy. Where applicable, these participants will be considered Affected Control Subjects.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA, RNA and specific biomarker assessments for whole blood SMN protein levels, plasma and
      serum for exploratory metabolomics profiling, skin biopsy for fibroblast cell line
      establishment (iPS cell line studies)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pre-symptomatic or newly diagnosed infants and children with Spinal Muscular Atrophy (SMA)
        types 1, 2, or 3; OR unaffected parents and siblings of enrolled infants and children with
        SMA; OR control subjects: infants and children who are not affected with SMA
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For affected subjects: genetic diagnosis of SMA

          -  For unaffected family members: parent or sibling of any age (without genetic diagnosis
             of SMA) of affected subject enrolled in study

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathryn J Swoboda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kendall Trautman</last_name>
    <phone>617-724-2523</phone>
    <email>ktrautman@mgh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gisel Dannehl</last_name>
    <phone>617-643-6451</phone>
    <email>gdannehl@mgh.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kendall Trautman</last_name>
      <phone>617-724-2523</phone>
      <email>ktrautman@mgh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Gisel Dannehl</last_name>
      <phone>617-643-6451</phone>
      <email>gdannehl@mgh.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kathryn J Swoboda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.medicalhomeportal.org/</url>
    <description>Medical Home Portal, University of Utah Department of Pediatrics</description>
  </link>
  <reference>
    <citation>Bitton A, Martin C, Landon BE. A nationwide survey of patient centered medical home demonstration projects. J Gen Intern Med. 2010 Jun;25(6):584-92. doi: 10.1007/s11606-010-1262-8.</citation>
    <PMID>20467907</PMID>
  </reference>
  <reference>
    <citation>Butchbach ME, Rose FF Jr, Rhoades S, Marston J, McCrone JT, Sinnott R, Lorson CL. Effect of diet on the survival and phenotype of a mouse model for spinal muscular atrophy. Biochem Biophys Res Commun. 2010 Jan 1;391(1):835-40. doi: 10.1016/j.bbrc.2009.11.148. Epub 2009 Nov 27.</citation>
    <PMID>19945425</PMID>
  </reference>
  <reference>
    <citation>Butchbach ME, Singh J, Thorsteinsdóttir M, Saieva L, Slominski E, Thurmond J, Andrésson T, Zhang J, Edwards JD, Simard LR, Pellizzoni L, Jarecki J, Burghes AH, Gurney ME. Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy. Hum Mol Genet. 2010 Feb 1;19(3):454-67. doi: 10.1093/hmg/ddp510. Epub 2009 Nov 6.</citation>
    <PMID>19897588</PMID>
  </reference>
  <reference>
    <citation>Chung BH, Wong VC, Ip P. Spinal muscular atrophy: survival pattern and functional status. Pediatrics. 2004 Nov;114(5):e548-53. Epub 2004 Oct 18.</citation>
    <PMID>15492357</PMID>
  </reference>
  <reference>
    <citation>Cobben JM, Lemmink HH, Snoeck I, Barth PA, van der Lee JH, de Visser M. Survival in SMA type I: a prospective analysis of 34 consecutive cases. Neuromuscul Disord. 2008 Jul;18(7):541-4. doi: 10.1016/j.nmd.2008.05.008. Epub 2008 Jun 24.</citation>
    <PMID>18579378</PMID>
  </reference>
  <reference>
    <citation>Lefebvre S, Bürglen L, Reboullet S, Clermont O, Burlet P, Viollet L, Benichou B, Cruaud C, Millasseau P, Zeviani M, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995 Jan 13;80(1):155-65.</citation>
    <PMID>7813012</PMID>
  </reference>
  <reference>
    <citation>Lemoine TJ, Swoboda KJ, Bratton SL, Holubkov R, Mundorff M, Srivastava R. Spinal muscular atrophy type 1: are proactive respiratory interventions associated with longer survival? Pediatr Crit Care Med. 2012 May;13(3):e161-5. doi: 10.1097/PCC.0b013e3182388ad1.</citation>
    <PMID>22198810</PMID>
  </reference>
  <reference>
    <citation>Lorson CL, Hahnen E, Androphy EJ, Wirth B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci U S A. 1999 May 25;96(11):6307-11.</citation>
    <PMID>10339583</PMID>
  </reference>
  <reference>
    <citation>Mailman MD, Heinz JW, Papp AC, Snyder PJ, Sedra MS, Wirth B, Burghes AH, Prior TW. Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genet Med. 2002 Jan-Feb;4(1):20-6. doi: 10.1097/00125817-200201000-00004.</citation>
    <PMID>11839954</PMID>
  </reference>
  <reference>
    <citation>Mannaa MM, Kalra M, Wong B, Cohen AP, Amin RS. Survival probabilities of patients with childhood spinal muscle atrophy. J Clin Neuromuscul Dis. 2009 Mar;10(3):85-9. doi: 10.1097/CND.0b013e318190310f.</citation>
    <PMID>19258855</PMID>
  </reference>
  <reference>
    <citation>Oskoui M, Levy G, Garland CJ, Gray JM, O'Hagen J, De Vivo DC, Kaufmann P. The changing natural history of spinal muscular atrophy type 1. Neurology. 2007 Nov 13;69(20):1931-6.</citation>
    <PMID>17998484</PMID>
  </reference>
  <reference>
    <citation>Rudnik-Schöneborn S, Berg C, Zerres K, Betzler C, Grimm T, Eggermann T, Eggermann K, Wirth R, Wirth B, Heller R. Genotype-phenotype studies in infantile spinal muscular atrophy (SMA) type I in Germany: implications for clinical trials and genetic counselling. Clin Genet. 2009 Aug;76(2):168-78. doi: 10.1111/j.1399-0004.2009.01200.x.</citation>
    <PMID>19780763</PMID>
  </reference>
  <reference>
    <citation>Stange KC, Nutting PA, Miller WL, Jaén CR, Crabtree BF, Flocke SA, Gill JM. Defining and measuring the patient-centered medical home. J Gen Intern Med. 2010 Jun;25(6):601-12. doi: 10.1007/s11606-010-1291-3.</citation>
    <PMID>20467909</PMID>
  </reference>
  <reference>
    <citation>Stille C, Turchi RM, Antonelli R, Cabana MD, Cheng TL, Laraque D, Perrin J; Academic Pediatric Association Task Force on Family-Centered Medical Home. The family-centered medical home: specific considerations for child health research and policy. Acad Pediatr. 2010 Jul-Aug;10(4):211-7. doi: 10.1016/j.acap.2010.05.002.</citation>
    <PMID>20605546</PMID>
  </reference>
  <reference>
    <citation>Swoboda KJ, Prior TW, Scott CB, McNaught TP, Wride MC, Reyna SP, Bromberg MB. Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Ann Neurol. 2005 May;57(5):704-12.</citation>
    <PMID>15852397</PMID>
  </reference>
  <reference>
    <citation>Swoboda KJ, Kissel JT, Crawford TO, Bromberg MB, Acsadi G, D'Anjou G, Krosschell KJ, Reyna SP, Schroth MK, Scott CB, Simard LR. Perspectives on clinical trials in spinal muscular atrophy. J Child Neurol. 2007 Aug;22(8):957-66. Review.</citation>
    <PMID>17761650</PMID>
  </reference>
  <reference>
    <citation>Swoboda KJ, Scott CB, Reyna SP, Prior TW, LaSalle B, Sorenson SL, Wood J, Acsadi G, Crawford TO, Kissel JT, Krosschell KJ, D'Anjou G, Bromberg MB, Schroth MK, Chan GM, Elsheikh B, Simard LR. Phase II open label study of valproic acid in spinal muscular atrophy. PLoS One. 2009;4(5):e5268. doi: 10.1371/journal.pone.0005268. Epub 2009 May 14.</citation>
    <PMID>19440247</PMID>
  </reference>
  <reference>
    <citation>Swoboda KJ. Seize the day: Newborn screening for SMA. Am J Med Genet A. 2010 Jul;152A(7):1605-7. doi: 10.1002/ajmg.a.33519.</citation>
    <PMID>20583173</PMID>
  </reference>
  <reference>
    <citation>Wan L, Battle DJ, Yong J, Gubitz AK, Kolb SJ, Wang J, Dreyfuss G. The survival of motor neurons protein determines the capacity for snRNP assembly: biochemical deficiency in spinal muscular atrophy. Mol Cell Biol. 2005 Jul;25(13):5543-51.</citation>
    <PMID>15964810</PMID>
  </reference>
  <reference>
    <citation>Wirth B, Brichta L, Schrank B, Lochmüller H, Blick S, Baasner A, Heller R. Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Hum Genet. 2006 May;119(4):422-8. Epub 2006 Mar 1.</citation>
    <PMID>16508748</PMID>
  </reference>
  <reference>
    <citation>Zerres K, Rudnik-Schöneborn S. Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol. 1995 May;52(5):518-23.</citation>
    <PMID>7733848</PMID>
  </reference>
  <reference>
    <citation>Kolb SJ, Coffey CS, Yankey JW, Krosschell K, Arnold WD, Rutkove SB, Swoboda KJ, Reyna SP, Sakonju A, Darras BT, Shell R, Kuntz N, Castro D, Iannaccone ST, Parsons J, Connolly AM, Chiriboga CA, McDonald C, Burnette WB, Werner K, Thangarajh M, Shieh PB, Finanger E, Cudkowicz ME, McGovern MM, McNeil DE, Finkel R, Kaye E, Kingsley A, Renusch SR, McGovern VL, Wang X, Zaworski PG, Prior TW, Burghes AH, Bartlett A, Kissel JT; NeuroNEXT Clinical Trial Network and on behalf of the NN101 SMA Biomarker Investigators. Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study. Ann Clin Transl Neurol. 2016 Jan 21;3(2):132-45. doi: 10.1002/acn3.283. eCollection 2016 Feb.</citation>
    <PMID>26900585</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 1, 2016</study_first_submitted>
  <study_first_submitted_qc>July 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2016</study_first_posted>
  <last_update_submitted>April 18, 2017</last_update_submitted>
  <last_update_submitted_qc>April 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Kathryn J Swoboda</investigator_full_name>
    <investigator_title>Katherine B. Sims MD Endowed Chair in Neurogenetics</investigator_title>
  </responsible_party>
  <keyword>SMA</keyword>
  <keyword>Werdnig-Hoffmann disease</keyword>
  <keyword>Kugelberg-Welander disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy, Spinal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The National Institute of Child Health and Human Development has a contract with the American College of Medical Genomics and the Newborn Screening Translational Research Network (NBSTRN) in collaboration with the bioinformatics group at the Cincinnati Children's Hospital to develop a national database for data capture and management for all the follow-up data to be collected for those who agree to participate in the research study. The investigators will share deidentified data with the NBSTRN database.
The investigators will also submit large-scale human genomic data as well as relevant associated data (e.g., phenotype and exposure data) to an NIH-designated data repository in a timely manner, as indicated by the NIH Genomic Data Sharing policy.
Aggregate Data will be available for submission/general research use.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

